Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505

Text Correction

As an addition to the original publication [1], we conducted a supplementary data analysis to clearly reflect the contributions of all team members.

A correction has been made to 2. Results and Discussion, 2.2. Drug Release from the Collagen Carrier, Paragraph 4:

On the other hand, the exponential model with the Korsmeyer–Peppas (KP) component b·tⁿ_r [57], where b represents the kinetic constant characteristic of the drug/polymer system, t_r is the release time, and n is the diffusional release exponent, fits the data obtained for Levofloxacin with greater accuracy (R² = 0.99551)—see Figures S17 and S18. The Korsmeyer–Peppas model combined with the first-order exponential model seems to be an appropriate model for more structurally complicated substances and polymer carriers.

Addition of Supplementary Materials

As an addition to the original publication [1], we conducted a supplementary data analysis to clearly reflect the contributions of all team members and updated the Supplementary Materials. The newly added Supplementary Materials part appears below:

Figure S17 Tetracaine release profiles of drug carriers with the kinetic model and its parameters—first-order exponential kinetic model and comparison with the same exponential model including the Korsmeyer–Peppas (KP) component; Figure S18 Levofloxacin release profiles of drug carriers with the kinetic model and its parameters—first-order exponential kinetic model and comparison with the same exponential model including the Korsmeyer–Peppas (KP) component.

Addition of an Author

In the original publication [1], Mehrdad Rafat was not included as an author. Mehrdad Rafat belongs to the new affiliations 2 and 3:

2. LinkoCare Life Sciences AB, 16975 Stockholm, Sweden; [email protected]

3. NaturaLens AB, 58330 Linköping, Sweden

The corrected Author Contributions statement appears here.

Conceptualization: P.U. and I.K.; investigation: P.U., B.H., J.Š., P.Š., T.Š., P.S., M.R. and I.K.; methodology: P.U., P.S. and I.K.; formal analysis P.U., B.H. and I.K.; visualization: P.U., B.H., J.Š. and I.K.; resources: M.R.; data analysis: P.U. and M.R.; writing—original draft: P.U., B.H., P.Š. and I.K.; writing—review and editing: P.U. and I.K.; funding acquisition: P.U., I.K. and P.S. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

In the original publication [1], the Conflicts of Interest statement of Mehrdad Rafat was not included. The updated Conflicts of Interest should read as follows: Author Mehrdad Rafat was employed by the companies LinkoCare Life Sciences AB and NaturaLens AB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

Reference

1. Urbánek, P.; Šuly, P.; Ševčík, J.; Hanulíková, B.; Kuřitka, I.; Šopík, T.; Rafat, M.; Stodůlka, P. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals; 2023; 16, 505. [DOI: https://dx.doi.org/10.3390/ph16040505] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37111260]